Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VIR BIOTECHNOLOGY, INC.

(VIR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/14/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
45.54(c) 43.74(c) 44.45(c) 43.82(c) 46.15(c) Last
637 691 580 980 515 936 771 976 1 770 658 Volume
+0.02% -3.95% +1.62% -1.42% +5.32% Change
More quotes
Financials (USD)
Sales 2021 331 M - -
Net income 2021 -331 M - -
Net cash position 2021 364 M - -
P/E ratio 2021 -17,4x
Yield 2021 -
Sales 2022 543 M - -
Net income 2022 -226 M - -
Net cash position 2022 695 M - -
P/E ratio 2022 -26,8x
Yield 2022 -
Capitalization 6 001 M 6 001 M -
EV / Sales 2021 17,0x
EV / Sales 2022 9,77x
Nbr of Employees 340
Free-Float 87,0%
More Financials
Company
Vir Biotechnology, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments to treat and prevent serious infectious diseases. Its technology platforms are focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid (siRNA). Its pipeline consists of product candidates targeting hepatitis B virus (HBV), influenza A, human immunodeficiency virus (HIV) and... 
Sector
Biotechnology & Medical Research
Calendar
06/25 | 08:00amPresentation
More about the company
Ratings of Vir Biotechnology, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about VIR BIOTECHNOLOGY, INC.
06/15AstraZeneca antibody cocktail fails to prevent COVID-19 in large trial
RE
06/14VIR BIOTECHNOLOGY  : Announces Multiple Abstracts Highlighting New Hepatitis B D..
AQ
06/04VIR BIOTECHNOLOGY  : Baird Starts Vir Biotechnology at Neutral with $45 Price Ta..
MT
06/04U.S. authorizes Regeneron's COVID-19 antibody therapy for injection
RE
06/04Regeneron's Covid-19 Drug Is Authorized for Injection
DJ
06/02Vir Biotechnology to Participate in the Goldman Sachs 42nd Annual Global Heal..
GL
05/27VIR BIOTECHNOLOGY  : GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Re..
PU
05/27VIR BIOTECHNOLOGY, INC.  : Other Events, Financial Statements and Exhibits (form..
AQ
05/27Today on Wall Street: When strategies collide
05/27SECTOR UPDATE : Health Care Stocks Flat Ahead of Thursday Opener
MT
05/27Xencor to Receive Royalties on Worldwide Sales of Vir, GlaxoSmithKline COVID-..
MT
05/27UPDATE : Vir, GlaxoSmithKline Secure Emergency Use Approval in US for Treatment ..
MT
05/27VIR BIOTECHNOLOGY  : GlaxoSmithKline Secure Emergency Use Approval in US for Sot..
MT
05/27India's Zydus Cadila seeks human trial approval for COVID-19 antibody cocktai..
RE
05/26GLAXOSMITHKLINE  : GSK-Vir Sotrovimab Treatment for COVID-19 Gets Emergency Use ..
MT
More news
News in other languages on VIR BIOTECHNOLOGY, INC.
06/16Bons résultats pour le cocktail anti-COVID-19 de Regeneron et Roche
06/15ASTRAZENECA  : Le traitement par anticorps échoue à prévenir les symptômes du CO..
05/28Résumé des principales informations économiques du vendredi 28 mai 2021
05/27COVID  : oltre 168 mln casi e 3,49 mln morti nel mondo
05/27MIDDAY BRIEFING - Unternehmen und Märkte -2-
More news
Analyst Recommendations on VIR BIOTECHNOLOGY, INC.
More recommendations
Chart VIR BIOTECHNOLOGY, INC.
Duration : Period :
Vir Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIR BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 74,29 $
Last Close Price 46,15 $
Spread / Highest target 193%
Spread / Average Target 61,0%
Spread / Lowest Target -28,5%
EPS Revisions
Managers and Directors
NameTitle
George A. Scangos President, Chief Executive Officer & Director
Howard Horn CFO, Secretary & Principal Accounting Officer
Vicki L. Sato Non-Executive Chairman
Michael E. Kamarck Chief Technology Officer
Phil Pang Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VIR BIOTECHNOLOGY, INC.72.33%6 001
MODERNA, INC.90.67%79 980
LONZA GROUP LTD14.63%52 508
IQVIA HOLDINGS INC.33.76%45 934
CELLTRION, INC.-24.79%32 465
SEAGEN INC.-10.75%28 367